Schering Plough’s Bridion Faces FDA Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concerns render anesthesia injection “not approvable” in U.S.
You may also be interested in...
Sugammadex Review: Has Merck Finally Put Safety Concerns To Rest?
Adequacy of data on risks of hypersensitivity/anaphylaxis and cardiac dysrhythmia with neuromuscular blockade reversal agent are focus of FDA advisory committee review.
Merck Comes Prepared This Time As Sugammadex Faces Second Advisory Committee
After failing to submit safety data on time during the drug’s first FDA review, Merck has its data together and is armed with a new hypersensitivity study in advance of the second panel review for its anesthesia product.
Schering Plans Bridion Clinical Trial To Address FDA’s Hypersensitivity Concerns
Company expects to initiate the trial for the novel anesthesia injection this year.